367 related articles for article (PubMed ID: 27216065)
21. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
Ibrahim M; Andries K; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V; Veziris N
Antimicrob Agents Chemother; 2007 Mar; 51(3):1011-5. PubMed ID: 17178794
[TBL] [Abstract][Full Text] [Related]
22. Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.
Mourik BC; de Knegt GJ; Verbon A; Mouton JW; Bax HI; de Steenwinkel JEM
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739784
[No Abstract] [Full Text] [Related]
23. Rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis by the direct thin-layer agar method.
Robledo J; Mejia GI; Paniagua L; Martin A; Guzmán A
Int J Tuberc Lung Dis; 2008 Dec; 12(12):1482-4. PubMed ID: 19017461
[TBL] [Abstract][Full Text] [Related]
24. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.
Lalande V; Truffot-Pernot C; Paccaly-Moulin A; Grosset J; Ji B
Antimicrob Agents Chemother; 1993 Mar; 37(3):407-13. PubMed ID: 8384811
[TBL] [Abstract][Full Text] [Related]
25. Fighting tuberculosis by drugs targeting nonreplicating
Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
[TBL] [Abstract][Full Text] [Related]
26. The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats.
Baldan HM; De Rosa HJ; Brunetti IL; Ximenes VF; Machado RG
Biopharm Drug Dispos; 2007 Nov; 28(8):409-13. PubMed ID: 17828712
[TBL] [Abstract][Full Text] [Related]
27. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
28. Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
Mashele SA; Steel HC; Matjokotja MT; Rasehlo SSM; Anderson R; Cholo MC
J Glob Antimicrob Resist; 2022 Jun; 29():343-352. PubMed ID: 35339735
[TBL] [Abstract][Full Text] [Related]
29. Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.
De Groote MA; Gruppo V; Woolhiser LK; Orme IM; Gilliland JC; Lenaerts AJ
Antimicrob Agents Chemother; 2012 Feb; 56(2):731-8. PubMed ID: 22143517
[TBL] [Abstract][Full Text] [Related]
30. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
[TBL] [Abstract][Full Text] [Related]
32. Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
Li SY; Tasneen R; Tyagi S; Soni H; Converse PJ; Mdluli K; Nuermberger EL
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630203
[TBL] [Abstract][Full Text] [Related]
33. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
Ahn HC; Lee YC
Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
[TBL] [Abstract][Full Text] [Related]
34. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.
Hu Y; Coates AR; Mitchison DA
Int J Tuberc Lung Dis; 2006 Mar; 10(3):317-22. PubMed ID: 16562713
[TBL] [Abstract][Full Text] [Related]
35. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies.
Zhang N; Strydom N; Tyagi S; Soni H; Tasneen R; Nuermberger EL; Savic RM
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907182
[TBL] [Abstract][Full Text] [Related]
37. [Prevention of resistance to rifampicin by pyrazinamide in experimental tuberculosis in the mouse].
Grosset J; Truffot-Pernot C; Poggi S; Lecoeur H; Chastang C
Rev Mal Respir; 1985; 2(4):205-8. PubMed ID: 3937188
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens.
Hillemann D; Rüsch-Gerdes S; Richter E
J Clin Microbiol; 2007 Aug; 45(8):2635-40. PubMed ID: 17537937
[TBL] [Abstract][Full Text] [Related]
39. Genotypic analysis of isoniazid and rifampin resistance in drug-resistant clinical Mycobacterium tuberculosis complex isolates in southern Turkey.
Aslan G; Tezcan S; Serin MS; Emekdas G
Jpn J Infect Dis; 2008 Jul; 61(4):255-60. PubMed ID: 18653964
[TBL] [Abstract][Full Text] [Related]
40. Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure.
Hu Y; Pertinez H; Liu Y; Davies G; Coates A
J Antimicrob Chemother; 2019 Jun; 74(6):1627-1633. PubMed ID: 30789209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
